Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CAR T cells KITE-197

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) with an as of yet undisclosed target, with potential immunomodulating and antineoplastic activities. Upon administration, autologous CAR T cells KITE-197 specifically recognize and kill tumor cells expressing the as of yet undisclosed antigen target. This results in a cytotoxic T-lymphocyte (CTL) response against these tumor cells, thereby causing tumor cell lysis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CAR-T cells KITE-197
Code name:KITE 197
KITE-197
KITE197
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search